Portfolio

ACACIA PHARMA

Acacia Pharma is in phase IIa trials with repurposed molecules for the treatments of xerostomia, chemothreapy induced nausea & vomiting and cachexia in cancer care patients.

For further information: www.acaciapharma.com

Allocure develops cell therapies for the treatment of acute kidney injury. AC607, entering phase 2 clinical development, is a selection of mesenchymal stem cells (MSC), which can be administered off-the-shelf to any patient in need without requiring tissue matching or immunosuppressants.

For further information: www.allocure.com

Asante Solutions, Inc.

Asante Solutions, Inc. has developed an easy-to-use, disposable insulin pump that is affordable, reliable, and have strong appeal to patients in terms of user friendliness and physical appearance. Initially, the pump system will be used for the treatment of Type 1 diabetes.

For further information: www.asantesolutions.com

BoneSupport

BONESUPPORT develops injectable radio opaque bone void fillers that rapidly remodel to bone, can be combined with antibiotics and are capable of being delivered percutaneously. It markets and sells the injectable bone replacement material CERAMENT™ in EU and USA for use in trauma and bone infections.

For further information: www.bonesupport.se

CELLADON

Celladon is developing the drug MYDICAR®, that delivers the gene for the SERCA2a enzyme to the heart muscle cells, for heart failure. A Phase 2 clinical trial with MYDICAR®, shows sustained improvement at one year in cardiac function parameters and quality of life.

For further information: www.celladon.net

DBV Technologies

DBV Technologies is the only company in the world whose products are designed to epicutaneously (via a skin patch) deliver allergens for Epicutaneous Immunotherapy (EPIT) against food allergies such as peanut and milk.

For further information: www.dbv-technologies.com

ENTEROME BIOSCIENCE

Enterome develops diagnostic tests based on novel biomarkers for chronic and challenging medical conditions relating to abnormalities of bacterial composition of the human intestine (metabolic and bowel diseases).

For further information: www.enterome.com

EpiTherapeutics

EpiTherapeutics is developing novel innovative cancer drugs based on the world leading research in epigenetics conducted by Professor Kristian Helin and his group at Biotech Research & Innovation Centre (BRIC) at University of Copenhagen.

For further information: www.epitherapeutics.com

Nexstim

Nexstim is commercializing a system for Navigated Brain Stimulation (NBS), enabling pre-surgical mapping of the critical functions of the cortex, neurodiagnostics, as well as neurotherapeutical applications such as stroke rehabilitation.

For further information: www.nexstim.com

Syntaxin LTD.

Syntaxin discovers and develops a new class of biopharmaceuticals to treat disease through selective inhibition of cell secretory processes. The technology has the potential for developing treatments in for instance pain, over active bladder, acromegaly and cancer.

For further information: www.syntaxin.com

Veloxis Pharmaceuticals A/S

Based on its patented delivery technology, MeltDose®, Veloxis Pharmaceuticals has taken one project all the way through clinical development to the market. Its pipeline includes a phase III product for immuno-suppression, specifically in organ transplantation.

For further information: www.veloxis.com